For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced mortality, myocardial ...

In addition to ensuring equitable access to the glucagon-like peptide-1 (GLP-1) receptor agonists, the medical community ...

More than 48 million Americans 12 years or older had a substance use disorder in 2022, yet only 24 percent received treatment ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Garner, MD, Medical Director at SimpleFixRx to review it all for accuracy. Dr, Garner said, "Glucagon-like peptide-1 (GLP-1) ...

Researchers looked at the health records of 17 million Americans with obesity and determined that between 2022 and 2023, ...

Medically reviewed by Danielle Weiss, MD After losing extra pounds on Ozempic (semaglutide), some are finding themselves ...

A study published Wednesday suggests a surprising side effect of GLP-1 drugs such as Ozempic: they can be effective at ...